false2024Q3000160062012-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureauph:segmentutr:sqftauph:extension_option00016006202024-01-012024-09-3000016006202024-11-0600016006202024-09-3000016006202023-12-310001600620us-gaap:RelatedPartyMember2024-09-300001600620us-gaap:RelatedPartyMember2023-12-310001600620us-gaap:ProductMember2024-07-012024-09-300001600620us-gaap:ProductMember2023-07-012023-09-300001600620us-gaap:ProductMember2024-01-012024-09-300001600620us-gaap:ProductMember2023-01-012023-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2024-07-012024-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2023-07-012023-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2024-01-012024-09-300001600620auph:LicenseRoyaltyAndCollaborationRevenueMember2023-01-012023-09-3000016006202024-07-012024-09-3000016006202023-07-012023-09-3000016006202023-01-012023-09-300001600620us-gaap:CommonStockMember2024-06-300001600620us-gaap:AdditionalPaidInCapitalMember2024-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001600620us-gaap:RetainedEarningsMember2024-06-3000016006202024-06-300001600620us-gaap:CommonStockMember2024-07-012024-09-300001600620us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001600620us-gaap:RetainedEarningsMember2024-07-012024-09-300001600620us-gaap:CommonStockMember2024-09-300001600620us-gaap:AdditionalPaidInCapitalMember2024-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001600620us-gaap:RetainedEarningsMember2024-09-300001600620us-gaap:CommonStockMember2023-06-300001600620us-gaap:AdditionalPaidInCapitalMember2023-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001600620us-gaap:RetainedEarningsMember2023-06-3000016006202023-06-300001600620us-gaap:CommonStockMember2023-07-012023-09-300001600620us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001600620us-gaap:RetainedEarningsMember2023-07-012023-09-300001600620us-gaap:CommonStockMember2023-09-300001600620us-gaap:AdditionalPaidInCapitalMember2023-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001600620us-gaap:RetainedEarningsMember2023-09-3000016006202023-09-300001600620us-gaap:CommonStockMember2023-12-310001600620us-gaap:AdditionalPaidInCapitalMember2023-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001600620us-gaap:RetainedEarningsMember2023-12-310001600620us-gaap:CommonStockMember2024-01-012024-09-300001600620us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001600620us-gaap:RetainedEarningsMember2024-01-012024-09-300001600620us-gaap:CommonStockMember2022-12-310001600620us-gaap:AdditionalPaidInCapitalMember2022-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001600620us-gaap:RetainedEarningsMember2022-12-3100016006202022-12-310001600620us-gaap:CommonStockMember2023-01-012023-09-300001600620us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001600620us-gaap:RetainedEarningsMember2023-01-012023-09-3000016006202024-01-012024-03-310001600620us-gaap:EmployeeSeveranceMemberauph:StrategicRestructuringPlanMemberus-gaap:SubsequentEventMember2024-11-072024-11-070001600620us-gaap:EmployeeSeveranceMemberauph:StrategicRestructuringPlanMembersrt:MinimumMembersrt:ScenarioForecastMember2024-10-012024-12-310001600620us-gaap:EmployeeSeveranceMemberauph:StrategicRestructuringPlanMembersrt:MaximumMembersrt:ScenarioForecastMember2024-10-012024-12-310001600620auph:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001600620auph:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300001600620auph:MajorCustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001600620auph:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001600620srt:MinimumMember2024-01-012024-09-300001600620srt:MaximumMember2024-01-012024-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberauph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:CorporateBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2024-09-300001600620us-gaap:CommercialPaperMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:USTreasuryBillSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:USTreasuryBondSecuritiesMember2024-09-300001600620us-gaap:FairValueInputsLevel1Member2024-09-300001600620us-gaap:FairValueInputsLevel2Member2024-09-300001600620us-gaap:FairValueInputsLevel3Member2024-09-300001600620us-gaap:FairValueInputsLevel1Memberauph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberauph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberauph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620auph:CashCashEquivalentsAndRestrictedCashMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:CorporateBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2023-12-310001600620us-gaap:CommercialPaperMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2023-12-310001600620us-gaap:FairValueInputsLevel1Member2023-12-310001600620us-gaap:FairValueInputsLevel2Member2023-12-310001600620us-gaap:FairValueInputsLevel3Member2023-12-310001600620us-gaap:FairValueInputsLevel2Member2023-01-012023-12-310001600620us-gaap:FairValueInputsLevel2Member2024-01-012024-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMember2024-01-012024-09-300001600620auph:ShortTermCorporateDebtSecuritiesMember2024-09-300001600620auph:ShortTermCorporateDebtSecuritiesMember2024-01-012024-09-300001600620us-gaap:CommercialPaperMember2024-01-012024-09-300001600620us-gaap:USTreasuryBillSecuritiesMember2024-01-012024-09-300001600620us-gaap:USTreasuryBondSecuritiesMember2024-01-012024-09-300001600620auph:LongTermCorporateDebtSecuritiesMember2024-09-300001600620auph:LongTermCorporateDebtSecuritiesMember2024-01-012024-09-300001600620auph:CashCashEquivalentsAndRestrictedCashMember2023-01-012023-12-310001600620auph:ShortTermCorporateDebtSecuritiesMember2023-12-310001600620auph:ShortTermCorporateDebtSecuritiesMember2023-01-012023-12-310001600620us-gaap:CommercialPaperMember2023-01-012023-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2023-01-012023-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2023-01-012023-12-3100016006202023-01-012023-12-310001600620auph:LongTermCorporateDebtSecuritiesMember2023-12-310001600620auph:LongTermCorporateDebtSecuritiesMember2023-01-012023-12-310001600620us-gaap:PatentsMember2024-09-300001600620us-gaap:IntellectualPropertyMember2024-09-300001600620us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300001600620us-gaap:PatentsMember2023-12-310001600620us-gaap:IntellectualPropertyMember2023-12-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001600620us-gaap:LeaseholdImprovementsMember2024-09-300001600620us-gaap:LeaseholdImprovementsMember2023-12-310001600620us-gaap:OfficeEquipmentMember2024-09-300001600620us-gaap:OfficeEquipmentMember2023-12-310001600620us-gaap:FurnitureAndFixturesMember2024-09-300001600620us-gaap:FurnitureAndFixturesMember2023-12-310001600620us-gaap:ComputerEquipmentMember2024-09-300001600620us-gaap:ComputerEquipmentMember2023-12-310001600620auph:RockvilleMarylandMember2020-03-310001600620auph:RockvilleMarylandMember2024-09-300001600620auph:RockvilleMarylandMember2023-12-310001600620auph:RockvilleMarylandMember2023-01-012023-12-310001600620auph:RockvilleMarylandMember2020-03-120001600620auph:EdmontonAlbertaMember2022-10-310001600620auph:VispSwitzerlandMember2023-07-310001600620auph:VispSwitzerlandMember2024-09-300001600620auph:VispSwitzerlandMember2023-12-310001600620auph:VispSwitzerlandMember2024-07-012024-09-300001600620auph:VispSwitzerlandMember2024-01-012024-09-300001600620auph:BeinheimFranceMember2020-03-012020-03-310001600620auph:BeinheimFranceMember2023-07-310001600620auph:BeinheimFranceMember2024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-01-012020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMembersrt:MinimumMember2020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMembersrt:MaximumMember2020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2024-09-242024-09-240001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2024-07-012024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2024-07-012024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2024-01-012024-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2023-07-012023-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMemberus-gaap:ServiceMember2023-01-012023-09-3000016006202024-02-1500016006202024-02-292024-02-290001600620srt:MinimumMember2024-02-292024-02-290001600620srt:MaximumMember2024-02-292024-02-290001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2024-07-012024-09-300001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2023-07-012023-09-300001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2024-01-012024-09-300001600620auph:StockOptionsRSUsPerformanceAwardsAndESPPMember2023-01-012023-09-300001600620auph:AmendedAndRestatedEquityIncentivePlanMember2021-06-012021-06-300001600620us-gaap:EmployeeStockMember2021-06-300001600620us-gaap:EmployeeStockMember2024-01-012024-09-300001600620auph:RestrictedStockUnitsAndPerformanceAwardsMember2023-12-310001600620auph:RestrictedStockUnitsAndPerformanceAwardsMember2024-01-012024-09-300001600620auph:RestrictedStockUnitsAndPerformanceAwardsMember2024-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001600620us-gaap:InventoriesMember2024-07-012024-09-300001600620us-gaap:InventoriesMember2023-07-012023-09-300001600620us-gaap:InventoriesMember2024-01-012024-09-300001600620us-gaap:InventoriesMember2023-01-012023-09-300001600620auph:DrRobertTFosterMemberauph:EmployeeBenefitObligationsMember2024-09-300001600620auph:DrRobertTFosterMemberauph:EmployeeBenefitObligationsMember2023-12-310001600620auph:DrRobertTFosterMember2024-01-012024-09-300001600620auph:DrRobertTFosterMember2023-01-012023-12-310001600620us-gaap:EmployeeSeveranceMember2024-01-012024-09-300001600620us-gaap:ContractTerminationMember2024-01-012024-09-300001600620us-gaap:OtherRestructuringMember2024-01-012024-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________________________________
FORM 10-Q
_____________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_____________ to ________________
Commission file number: 001-36421
__________________________________________
Aurinia Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
__________________________________________
Alberta, Canada
(State or other jurisdiction of
incorporation or organization)
#140, 14315 - 118 Avenue
Edmonton, Alberta T5L 4S6
98-1231763
(Address of principal executive offices)(I.R.S. Employer
Identification Number)
(250) 744-2487
Registrant’s telephone number, including area code
_____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x 
Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of November 6, 2024, the registrant had 143,179,269 of common shares outstanding.
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common shares, no par valueAUPHThe Nasdaq Global Market LLC


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
TABLE OF CONTENTS
Page


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)September 30, 2024December 31, 2023
ASSETS
Current assets
Cash, cash equivalents, and restricted cash$37,142 $48,875 
Short-term investments311,605 301,614 
Accounts receivable, net36,483 24,089 
Inventories, net38,714 39,705 
Prepaid expenses and deposits13,815 9,486 
Other current assets2,700 1,031 
Total current assets440,459 424,800 
Non-current assets
Long-term investments— 201 
Other non-current assets868 1,517 
Property and equipment, net2,887 3,354 
Acquired intellectual property and other intangible assets, net4,509 4,977 
Finance right-of-use assets, net96,459 108,715 
Operating right-of-use assets, net4,179 4,498 
Total assets$549,361 $548,062 
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities56,770 54,389 
Deferred revenue4,304 4,813 
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively)
1,590 2,388 
Finance lease liabilities14,927 14,609 
Operating lease liabilities1,018 989 
Total current liabilities78,609 77,188 
Non-current liabilities
Finance lease liabilities65,955 75,479 
Operating lease liabilities5,951 6,530 
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively)
10,844 10,911 
Total liabilities161,359 170,108 
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY
Common shares - no par value, unlimited shares authorized, 143,109 and 143,833 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
1,206,613 1,200,218 
Additional paid-in capital119,773 120,788 
Accumulated other comprehensive loss(385)(730)
Accumulated deficit(937,999)(942,322)
Total shareholders' equity388,002 377,954 
Total liabilities and shareholders' equity$549,361 $548,062 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(in thousands, except per share data)
Three months endedNine months ended
September 30,September 30,
2024202320242023
(unaudited)
Revenue
Product revenue, net$55,503 $40,781 $158,604 $116,218 
License, collaboration, and royalty revenue
12,268 13,734 16,662 14,200 
Total revenue, net67,771 54,515 175,266 130,418 
Operating expenses
Cost of sales6,035 6,769 22,696 8,753 
Selling, general and administrative42,367 47,759 134,996 144,964 
Research and development3,047 13,605 12,678 39,413 
Restructuring expenses— — 7,755 — 
Other expense (income), net4,574 2,645 159 (695)
Total cost of sales and operating expenses56,023 70,778 178,284 192,435 
Income (Loss) from operations11,748 (16,263)(3,018)(62,017)
Interest expense(1,208)(1,400)(3,689)(1,465)
Interest income4,267 4,514 12,982 12,429 
Net income (loss) before income taxes14,807 (13,149)6,275 (51,053)
Income tax expense457 298 1,952 92 
Net income (loss)$14,350 $(13,447)$4,323 $(51,145)
Other comprehensive (loss) gain:
Unrealized gain on available-for-sale securities, net of tax of nil
474 73 345 114 
Comprehensive income (loss)$14,824 $(13,374)$4,668 $(51,031)
Net income (loss) per share:
Basic$0.10 $(0.09)$0.03 $(0.36)
Diluted$0.10 $(0.09)$0.03 $(0.36)
Weighted-average common shares outstanding:
Basic143,051 142,847 143,353 143,085 
Diluted145,651 142,847 145,010 143,085 
The accompanying notes are an integral part of these condensed consolidated financial statements.






2

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
(unaudited)
Common Shares
Three Months Ended September 30, 2024
SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2024142,984 $1,205,554 $112,270 $(859)$(952,349)$364,616 
Shares issued on exercise of stock options and vesting of restricted stock units125 1,059 (824)— — 235 
Share-based compensation— — 8,327 — — 8,327 
Unrealized gain on available-sale-securities, net— — — 474 — 474 
Net income— — — — 14,350 14,350 
Balance at September 30, 2024143,109 $1,206,613 $119,773 $(385)$(937,999)$388,002 
Common Shares
Three Months Ended September 30, 2023
SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2023143,369 $1,196,480 $98,832 $(1,020)$(902,000)$392,292 
Shares issued on exercise of stock options and vesting of restricted stock units236 2,080 (929)— — 1,151 
Shared-based compensation— — 11,808 — — 11,808 
Unrealized gain on available-for-sale securities, net— — — 73 — 73 
Net loss— — — — (13,447)(13,447)
Balance at September 30, 2023143,605 $1,198,560 $109,711 $(947)$(915,447)$391,877 

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
(unaudited)
Common Shares
Nine Months Ended September 30, 2024SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2023143,833 $1,200,218 $120,788 $(730)$(942,322)$377,954 
Shares issued on exercise of stock options and vesting of restricted stock units2,548 23,966 (23,320)— — 646 
Shares repurchased and cancelled, inclusive of transaction costs(3,424)(18,619)— — (18,619)
Issuance of common shares in conjunction with ESPP program152 1,048 (345)— — 703 
Share-based compensation— — 22,650 — — 22,650 
Unrealized gain on available-for-sale securities, net— — — 345 — 345 
Net income— — — — 4,323 4,323 
Balance at September 30, 2024143,109 $1,206,613 $119,773 $(385)$(937,999)$388,002 
Common Shares
Nine Months Ended September 30, 2023SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2022142,268 $1,185,309 $85,489 $(1,061)$(864,302)$405,435 
Shares issued on exercise of stock options and vesting of restricted stock units1,127 11,141 (8,117)— — 3,024 
Issuance of common shares in conjunction with ESPP program210 2,110 (1,204)— — 906 
Shared-based compensation— — 33,543 — — 33,543 
Unrealized gain on available-for-sale securities, net— — — 114 — 114 
Net loss— — — — (51,145)(51,145)
Balance at September 30, 2023143,605 $1,198,560 $109,711 $(947)$(915,447)$391,877 

The accompanying notes are an integral part of these condensed consolidated financial statements.
4

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended September 30,
20242023
(in thousands)(unaudited)
Cash flows from operating activities
Net income (loss)$4,323 $(51,145)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization14,583 6,698 
Net amortization of premiums and discounts on short-term investments(9,752)(8,836)
Share-based compensation expense22,650 33,543 
Foreign exchange on finance lease liability(718)(1,335)
Other, net220 (1,659)
Net changes in operating assets and liabilities
Accounts receivable, net(12,394)(24,463)
Inventories, net991 (8,984)
Prepaid expenses and other current assets(6,001)(2,889)
Non-current operating assets(12)(16)
Accounts payable, accrued and other liabilities934 11,812 
Operating lease liabilities(550)(499)
Net cash provided by (used in) operating activities 14,274 (47,773)
Cash flows from investing activities
Purchase of investments(461,140)(379,213)
Proceeds from investments461,448 391,287 
Upfront lease payment(44)(11,864)
Purchase of property and equipment— (419)
Capitalized patent costs(225)(240)
Net cash provided by (used in) investing activities 39 (449)
Cash flows from financing activities
Repurchase of common shares(18,435)— 
Principal portion of finance lease payments(8,959)(3,482)
Proceeds from exercise of stock options and employee share purchase plan1,348 3,929 
Cash (used in) provided by financing activities (26,046)447 
Net decrease in cash, cash equivalents, and restricted cash(11,733)(47,775)
Cash, cash equivalents, and restricted cash, beginning of period48,875 94,172 
Cash, cash equivalents, and restricted cash, end of period$37,142 $46,397 
Supplemental cash flow information
Cash received for interest$2,803 $3,559 
Cash paid for income taxes$(1,459)$(339)
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash, cash equivalents$36,630 $45,557 
Restricted cash512 840 
Total cash, cash equivalents, and restricted cash
$37,142 $46,397 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1.Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).
On February 15, 2024, the Company announced the conclusion of its previously announced strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25% and discontinued its AUR300 research and development program. For further discussion, refer to Note 19, Restructuring.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS® growth and the rapid development of AUR200. This restructuring will result in a workforce reduction of approximately 45% and Aurinia anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers.
The Company is also developing its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). On September 5, 2024, the Company announced the first participant has been dosed in a Phase 1 single ascending dose (SAD) study of AUR200. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025.
Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a United States commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
2.Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
6


These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.
Significant Accounting Policies
The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, other than as stated below.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories. Revenues from our two main customers represented approximately 49% and 38% of revenues for the nine months ended September 30, 2024. Revenues from our two main customers represented approximately 50% and 39% of revenues for the nine months ended September 30, 2023.
In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand for risk mitigation and supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As
7

of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses: Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares: The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
3.    Fair Value Measurements
The Company's financial instruments consist primarily of cash, cash equivalents, restricted cash, investments, accounts receivable, accounts payable, and accrued liabilities. The carrying value of accounts receivable, accounts payable, and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such
8

assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:
September 30, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds— 601 — 601 
Commercial paper— 2,028 — 2,028 
Treasury bills— 196,471 — 196,471 
Treasury bonds— 112,505 — 112,505 
Total financial assets$37,142 $311,605 $— $348,747 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
The Company's Level 1 instruments include cash, cash equivalents, and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 7 months for both periods. The Company's policy is for these investments to have an overall rating of A-1, or higher, by Standard & Poor's, or an equivalent rating by Moody’s or Fitch.
No credit loss allowance was recorded as of September 30, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, Cash, Cash Equivalents, Restricted Cash, and Investments, for the carrying amount and related unrealized gains (losses) by type of investment.
9

4.    Cash, Cash Equivalents, Restricted Cash, and Investments
As of September 30, 2024, and December 31, 2023, the Company had $348.7 million and $350.7 million, respectively of cash, cash equivalents, restricted cash, and investments summarized below. As of September 30, 2024, and December 31, 2023, $311.6 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.
September 30, 2024
(in thousands)Amortized CostUnrealized Gains
Unrealized Losses
Estimated Fair Value
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds599 2 — 601 
Commercial paper2,028 — — 2,028 
Treasury bills196,311 160 — 196,471 
Treasury bonds112,246 259 — 112,505 
Total cash, cash equivalents, restricted cash, and short-term investments
348,326 421 — 348,747 
Total long-term investment corporate bond— — — — 
Total cash, cash equivalents, restricted cash, and investments
$348,326 $421 $— $348,747 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash, and short-term investments
350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash, and investments
$350,616 $75 $(1)$350,690 

As of September 30, 2024, and December 31, 2023, accrued interest receivable from investments was $0.5 million and $0.7 million, respectively. During the three and nine months ended September 30, 2024, the Company had $0.5 million and $0.3 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. During the three and nine months ended September 30, 2023, the Company had $0.1 million and $0.1 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized gains on investments at September 30, 2024, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2024, and 2023.

The Company's short-term investments as of September 30, 2024 mature at various dates through August 2025.

5.    Inventories, net

Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of
10

regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.

The Company assesses recoverability of inventory each reporting period to determine if any write-down to net realizable value is necessary. As of September 30, 2024, and December 31, 2023, Aurinia recorded reserves of finished goods inventories of nil and $0.8 million, respectively, which were primarily related to potential inventory obsolescence.

The components of inventory, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process34,990 37,376 
Finished goods, net of reserve2,022 583 
Total inventories, net$38,714 $39,705 


6.Prepaid Expenses and Deposits
Prepaid expenses are as follows:

(in thousands)September 30, 2024December 31, 2023
Prepaid assets$7,730 $6,892 
Prepaid deposits4,189 1,345 
Prepaid insurance1,896 1,249 
Total prepaid expenses and deposits
$13,815 $9,486 


7.Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$2,073 $(1,354)$719 
Acquired intellectual property and reacquired rights15,126 (11,336)3,790 
Internal-use software implementation costs2,873 (2,873)— 
$20,072 $(15,563)$4,509 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
11

Amortization expense for the three months ended September 30, 2024, and 2023, was approximately $0.2 million and $0.5 million, respectively. Amortization for the nine months ended September 30, 2024, and 2023, was approximately $0.7 million and $1.4 million, respectively.
8.    Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,377)(1,910)
Property and equipment, net$2,887 $3,354 
9.    Lease Obligations
The Company has the following lease obligations:
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2024, the Company had a right-of-use (ROU) asset of $4.1 million and lease liability of $6.8 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right-of-use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.
When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at the lease commencement date on March 12, 2020. The incremental borrowing rate applied to the lease liability was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.
For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for all leases for the three and nine months ended September 30, 2024, and September 30, 2023, were $0.2 million and $0.6 million, respectively.
12

Monoplant
At lease inception, the Company recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease. As the monoplant finance lease is denominated in Swiss francs, the company incurs unrealized and realized foreign exchange gains and losses each reporting period related to the valuation of the lease liability and timing of lease payments.

As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $95.6 million and $80.7 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three and nine months ended September 30, 2024, ROU amortization was $4.4 million and $13.1 million, respectively. For the three and nine months ended September 30, 2024, interest expense was $1.2 million and $3.7 million, respectively.
Beinheim
The Company entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that commenced operations during June 2024 with a lease term of seven years. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.
As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $0.8 million and $0.1 million, respectively.
The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:
As of September 30, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases6.95.27%
Finance lease
5.56.19%
Supplemental cash flow information related to leases are as follows:
Nine Months Ended
September 30,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows for finance leases
$(8,959)$(3,482)
Operating cash flows for finance leases
$(3,354)$(718)
Operating cash flows for operating leases
$(831)$(805)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations
$96,459 $113,069 
Finance lease liability arising from obtaining right-of-use assets
$80,882 $85,521 
13

Future maturities of lease liabilities as of September 30, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$4,295 $283 
202517,203 1,141 
202617,204 1,169 
202717,204 1,198 
202817,205 1,227 
Thereafter21,554 3,302 
Total lease payments
94,665 8,320 
Less: imputed interest
(13,783)(1,351)
Total
$80,882 $6,969 

10.Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2024December 31, 2023
Commercial accruals
$25,523 $16,216 
Employee accruals
14,180 22,486 
Trade payables
8,878 4,327 
Other accrued liabilities
4,672 5,190 
Accrued R&D projects
2,331 5,503 
Income taxes payable
1,007 667 
Restructuring accruals
179 — 
Total accounts payable and accrued liabilities$56,770 $54,389 

11.Deferred Compensation and Other Non-current Liabilities

The Company recorded other non-current liabilities of $10.8 million and $10.9 million as of September 30, 2024, and December 31, 2023, respectively. The balance for both periods primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors (the Board) on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.
12.License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.

As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $50.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with
14

additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.
On September 24, 2024, the Company announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat LN. As part of the December 2020 agreement with Otsuka, the Company is eligible to receive a payment of $10.0 million U.S. dollars upon approval in Japan along with low double-digit royalties on net sales once launched. As a result, the $10.0 million milestone was recognized as collaboration revenue in the quarter.
For the three and nine months ended September 30, 2024, the Company recognized $12.3 million and $16.7 million, respectively of license, collaboration, and royalty revenue from services provided under the Otsuka agreement. For the three and nine months ended September 30, 2023, the Company recognized $12.7 million and $13.2 million, respectively.

13.    Shareholder's Equity

On February 15, 2024, Aurinia announced that the Board had approved a share repurchase program of up to $150 million common shares of the Company, affirming its confidence in the Company's growth prospects.

On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws.
As of September 30, 2024, the Company had repurchased approximately 3.4 million of Aurinia's common shares for $18.6 million (including transaction costs, which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common shares and under Alberta law, the shares were cancelled and not reissued.
14.Net Income (Loss) per Common Share
Basic and diluted net loss per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. For the periods in a loss position, diluted net loss per share is the same as basic net loss per share. The treasury stock method is used to determine the dilutive effect of the Company's stock options, RSUs, performance awards and ESPP. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three Months Ended
 September 30,
Nine Months Ended
September 30,
(in thousands, except per share data)2024202320242023
Numerator:
Net income (loss) used for the calculation of basic and diluted EPS
$14,350 $(13,447)$4,323 $(51,145)
Denominator:
Weighted-average common shares outstanding, basic
143,051 142,847 143,353 143,085 
Effect of dilutive shares:
Stock options, RSUs, performance awards and ESPP
2,600 — 1,657 — 
Weighted-average diluted common shares outstanding, diluted
145,651 142,847 145,010 143,085 
Net income (loss) per share, basic
$0.10 $(0.09)0.03 (0.36)
Net income (loss) per share, diluted
$0.10 $(0.09)$0.03 $(0.36)
15

The Company did not include certain shares issuable under share-based compensation plans because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

15.Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of September 30, 2024, 0.9 million shares have been purchased under the ESPP.
In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.
Stock Options
The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent
16

remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.08 %3.92 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.0 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$3.82 $5.94 
The following table summarizes the option award activity for the nine months ended September 30, 2024:

September 30, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted325 5.89 
Exercised(125)5.18 
Forfeited or cancelled
(2,006)12.81 
Outstanding - September 30, 2024
9,750 $10.09 
Restricted Stock Units and Performance Awards
The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.
The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:
September 30, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,663 6.89 
Vested(2,422)9.50 
Forfeited(1,673)8.99 
Unvested balance - September 30, 2024
8,375 $7.96 
17

Share-based Compensation Expense
The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Research and development$306 $1,975 $(1,773)$5,679 
Selling, general and administrative7,812 9,560 23,427 26,969 
Capitalized under inventories209 273 996 895 
Share-based compensation expense$8,327 $11,808 $22,650 $33,543 
As of September 30, 2024, there was $25.7 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.

16.Income Taxes

The effective tax rates for the three and nine months ended September 30, 2024, and September 30, 2023, differed from the Canadian statutory rate applied to income or losses before income taxes primarily as a result of the mix of income, losses and valuation allowances.

The Company recognized an income tax expense of approximately $0.5 million and $2.0 million for the three and nine months ended September 30, 2024, respectively. The Company recognized an income tax expense of approximately $0.3 million and $0.1 million for the three and nine months ended September 30, 2023, respectively. The income tax expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.
17.Related Party Transactions
On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board on September 21, 2023. As of September 30, 2024, the Company had $0.8 million and $7.0 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of September 30, 2024, and December 31, 2023, the Company made payments of $0.4 million and $0.1 million, respectively for each period as a related party for the deferred compensation.
18.Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. Other than as described under Part II, Item I, the Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
18

19.Restructuring
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program.
As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:
(in thousands)
Nine Months Ended September 30, 2024
Employee severance and one time benefits
$6,075 
Contract terminations
1,105 
Other costs
575 
Total
$7,755 

20.Subsequent Events
Effective November 7, 2024, Aurinia appointed Craig Johnson to the Board. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry.
The Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. The information in this discussion contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, (the Exchange Act), which are subject to the “safe harbor” created by those sections, as well as “forward-looking information” as defined in applicable Canadian securities laws. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our anticipation of a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million, with post‑restructuring annualized cash-based operating expense savings of more than $40 million; our estimate that we will reduce our workforce by approximately 45%; our expectation that our restructuring will further improve operational efficiency; our estimate, based on our patient-specific estimated glomerular filtration rate (eGFR) dosing regimens, the average utilization in our clinical trials, and accounting for factors including mandatory rebates, channel discounts, and anticipated patient adherence, that we expect our average annualized net realizable revenue per patient to be approximately $70,000 to $75,000; timing for data the AUR200 SAD study; our belief that we have sufficient financial resources to fund our current plans for at least the next few years; and our potential to receive certain payments and royalties under our agreement with Otsuka Pharmaceuticals Co. Ltd., or Otsuka. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “propose,” “intend,” “continue,” “potential,” “possible,” “foreseeable,” “likely,” “unforeseen” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third-party studies and reports; that our IP rights are valid and do not infringe the IP rights of third parties; our assumptions relating to the capital required to fund operations for the next few years; the timing and ability to execute on our restructuring plans; the costs, benefits and scope of our restructuring plans; the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; assumptions relating to the capital required to fund operations for the next few years; assumptions relating to the progress of our pre-clinical activities that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading “Risk Factors” in Part I, Item 1A of our 2023 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 15, 2024 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Overview
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, we introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active LN. We continue to conduct clinical and regulatory activities to support the LUPKYNIS development program. We contracted with Otsuka as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories.
The price of LUPKYNIS is based on one unit of 60 capsules we refer to as a “wallet”. As of January 1, 2024, the wholesale acquisition cost (WAC) of a LUPKYNIS wallet is $4,898. Based on our patient-specific eGFR dosing regimens, the average utilization in our clinical trials, and accounting for factors including mandatory rebates, channel discounts, and anticipated patient adherence, duration of therapy and compliance, we have adjusted our expected average annualized net realizable revenue per patient to be approximately $70,000 - $75,000. When determining the price of LUPKYNIS, we considered the burden of LN disease in the context of value that LUPKYNIS offers to patients and the U.S. healthcare system.
20

On February 15, 2024, the Company announced the conclusion of its previously announced strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25% and discontinued its AUR300 research and development program. For further discussion, refer to Note 19, Restructuring.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS® growth and the rapid development of AUR200. The restructuring will result in a workforce reduction of approximately 45% and Aurinia anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers. The restructuring will also improve operational efficiency, with anticipated post-restructuring annualized cash savings of more than $40 million.
The Company is also developing its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
Recent Developments
On September 5, 2024, the Company announced the first participant has been dosed in a Phase 1 SAD study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF and APRIL. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025.
On September 24, 2024, the Company announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS in combination with mycophenolate mofetil (MMF) to treat LN. As part of the December 2020 agreement with Otsuka, the Company is eligible to receive a payment of $10.0 million U.S. dollars upon approval in Japan along with low double-digit royalties on net sales once launched. As a result, the $10.0 million milestone was recognized as collaboration revenue in the quarter.
In September 2024, the Board appointed Kevin Tang, President of Tang Capital Management, LLC, a life sciences-focused investment company that he founded in 2002, as a Director and Chair of the Board. Mr. Tang has more than 20 years of experience investing in, governing and leading companies in the biopharmaceutical industry. The Company also announced the acceptance of the conditional resignations of three directors who received less than majority support at the 2024 Annual General Meeting.
Effective November 7, 2024, Aurinia appointed Craig Johnson to the Board. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry.
The Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
Policies and Significant Judgments and Estimates
There have been no material changes to our critical accounting policies and significant judgments and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2023 other than as stated below.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute our products. Revenues from product sales are recognized when the customer obtains control of our product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer).
Our estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of
21

the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, we consider historical data, including patient mix to accrue for variable consideration related to inventory sold to our customers that has not yet been dispensed to patients. We use a data aggregator and historical claims to estimate variable consideration for inventory sold to our specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, we did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in our Annual Report on Form 10-K for the year ended December 31, 2023.
Results of Operations
Three and Nine Months ended September 30, 2024 compared to Three and Nine Months ended September 30, 2023
The following table sets forth our results of operations for the three and nine months ended September 30, 2024 and September 30, 2023.
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)20242023Change20242023Change
Revenue
Product revenue, net$55,503 $40,781 $14,722 $158,604 $116,218 $42,386 
License, collaboration, and royalty revenue
12,268 13,734 (1,466)16,662 14,200 2,462 
Total revenue, net67,771 54,515 13,256 175,266 130,418 44,848 
Operating expenses
Cost of sales6,035 6,769 (734)22,696 8,753 13,943 
Selling, general and administrative42,367 47,759 (5,392)134,996 144,964 (9,968)
Research and development3,047 13,605 (10,558)12,678 39,413 (26,735)
Restructuring expenses— — — 7,755 — 7,755 
Other expense (income), net4,574 2,645 1,929 159 (695)854 
Total cost of sales and operating expenses56,023 70,778 (14,755)178,284 192,435 (14,151)
Income (Loss) from operations11,748 (16,263)28,011 (3,018)(62,017)58,999 
Interest expense(1,208)(1,400)192 (3,689)(1,465)(2,224)
Interest income4,267 4,514 (247)12,982 12,429 553 
Net income (loss) before income taxes14,807 (13,149)27,956 6,275 (51,053)57,328 
Income tax expense457 298 159 1,952 92 1,860 
Net income (loss)$14,350 $(13,447)$27,797 $4,323 $(51,145)$55,468 
22

Total Revenue, Net
Total net revenue was $67.8 million and $54.5 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Total net revenue was $175.3 million and $130.4 million for the nine months ended September 30, 2024, and September 30, 2023, respectively.
We currently sell to two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and license, collaboration, and royalty revenue in the Otsuka Territories.
The percentage of total net revenues from our main customers were as follows:
Three Months Ended September 30,
Nine Months Ended September 30,
2024202320242023
Two main specialty pharmacies
81%77%87%90%
Collaboration partnership
16%21%11%9%
Product Revenue, Net
Net product revenue was $55.5 million and $40.8 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Net product revenue was $158.6 million and $116.2 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The increase in both periods is primarily due to increased LUPKYNIS sales to our two main specialty pharmacies, driven predominantly by further penetration of the LN market. Additionally, for the nine months ended September 30, 2024, we had sales of semi-finished product to Otsuka as Otsuka continues to commercialize in its territories.
The U.S. penetration can be demonstrated by a total of approximately 2,422 patients on therapy as of September 30, 2024, compared to approximately 1,939 patients on therapy as of September 30, 2023. Additionally, our 12-month persistency rate has increased to 57% at September 30, 2024, from approximately 54% at September 30, 2023.
License, Collaboration, and Royalty Revenues
License, collaboration, and royalty revenues were $12.3 million and $13.7 million for the three months ended September 30, 2024, and September 30, 2023, respectively. License, collaboration, and royalty revenues were $16.7 million and $14.2 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The revenue is primarily due to a $10.0 million milestone recognized in third quarter of 2024 for the Japanese Ministry of Health, Labour, and Welfare approval of LUPKYNIS and a $10.0 million milestone recognized in third quarter of 2023 for pricing and reimbursement approval in certain European jurisdictions, coupled with manufacturing services revenue from Otsuka related to shared capacity services that commenced in late June 2023.
Cost of Sales
Cost of sales was $6.0 million and $6.8 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Cost of sales was $22.7 million and $8.8 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The decrease for the three months ended September 30, 2024, is primarily due to inventory write downs and semi-finished product sales to Otsuka in the prior three months ended September 30, 2023. The increase for
23

the nine months ended September 30, 2024, is primarily due to the amortization of the monoplant finance right of use asset, which was placed into service in late June 2023 and therefore only partially impacted prior year results.
Gross Margin
Gross margin for the three months ended September 30, 2024, and September 30, 2023, was approximately 91% and 88%, respectively. Gross margin for the nine months ended September 30, 2024, and September 30, 2023, was approximately 87% and 93%, respectively.
Selling, General and Administrative Expenses
SG&A expenses decreased to $42.4 million for the three months ended September 30, 2024, compared to $47.8 million for the three months ended September 30, 2023. For the nine months ended September 30, 2024, and September 30, 2023, SG&A expenses were $135.0 million and $145.0 million, respectively. SG&A expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Salaries, incentive pay and employee benefits$17,563 $19,563 $57,493 $61,851 
Professional fees and services11,982 12,716 38,727 37,202 
Share-based compensation expense7,812 9,560 23,427 26,969 
Other public company costs, facility costs, insurance, information technology, amortization of property and equipment2,728 3,284 8,225 10,546 
Travel, trade shows and sponsorships2,282 2,636 7,124 8,396 
$42,367 $47,759 $134,996 $144,964 
The primary drivers for the decrease in both periods were lower employee related costs including share-based compensation and overhead costs due to the reduction in general and administrative headcount, which occurred late in the first quarter of 2024.
Research and Development Expenses
R&D expenses were $3.0 million and $13.6 million for the three months ended September 30, 2024, and September 30, 2023, respectively. For the nine months ended September 30, 2024, and September 30, 2023, R&D expenses were $12.7 million and $39.4 million, respectively. R&D expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Contract research organizations (CRO) and developmental expenses$1,380 $5,751 $6,486 $14,046 
Clinical supply and distribution354 2,208 2,353 8,355 
Salaries, incentive pay and employee benefits900 3,619 5,240 10,879 
Share-based compensation expense306 1,975 (1,773)5,679 
Other costs107 52 372 454 
$3,047 $13,605 $12,678 $39,413 

The primary drivers for the decrease in both periods were lower employee costs related to the reduction in headcount, which occurred late in the first quarter of 2024, a decrease of expenses related to ceasing our AUR300 development program, and lower expenses related to developing AUR200.
24

Restructuring Expenses
During the three and nine months ended September 30, 2024, restructuring expenses were approximately nil and $7.8 million and nil for the three and nine months ended September 30, 2023. Restructuring expenses primarily included employee severance, one-time benefit payments, and contract termination expenses related to the restructuring, which occurred late in the first quarter of 2024.
Other Expense (Income), net

Other expense (income), net was $4.6 million and $2.6 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Other expense (income), net was $0.2 million and $(0.7) million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The change is primarily driven by changes in the fair value assumptions related to our deferred compensation liability and the foreign exchange remeasurement of the monoplant lease liability, which commenced in June 2023 and is denominated in CHF.

Interest Expense
Interest expense was $1.2 million and $1.4 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Interest expense was $3.7 million and $1.5 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. The interest expense is due to the monoplant finance lease, which commenced in June 2023.

Interest Income

Interest income was $4.3 million and $4.5 million for the three months ended September 30, 2024, and September 30, 2023, respectively. Interest income was $13.0 million and $12.4 million for the nine months ended September 30, 2024, and September 30, 2023, respectively.
Liquidity and Capital Resources
As of September 30, 2024, we had cash, cash equivalents, and restricted cash of approximately $37.1 million and investments of $311.6 million compared to cash, cash equivalents, and restricted cash of $48.9 million and investments of $301.8 million at December 31, 2023. Cash needs were primarily related to the continued investment in LUPKYNIS commercialization activities, post approval commitments for LUPKYNIS, monoplant payments, share repurchases and restructuring related payments and were partially offset by an increase in cash receipts from sales of LUPKYNIS and cash payments from Otsuka. Cash, cash equivalents, restricted cash, and investments are primarily held in U.S. dollars. As of September 30, 2024, and December 31, 2023, we had working capital of $361.9 million and $347.6 million, respectively.
We are devoting the majority of our operational efforts and financial resources towards the commercialization and post- approval commitments for LUPKYNIS. Taking into consideration the cash, cash equivalents, and investments as of September 30, 2024, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, such as our FDA related post approval commitments, manufacturing and packaging commercial drug supply, funding our supporting commercial infrastructure, advancement of our pipeline, funding our working capital obligations and share repurchases for at least the next few years.

25

Cash Flow Summary
The following table summarizes our cash flows for the nine months ended September 30, 2024, and September 30, 2023:
Nine Months Ended September 30,
(in thousands)20242023
Net cash (used in) provided by:
Operating activities$14,274 $(47,773)
Investing activities39 (449)
Financing activities(26,046)447 
Net decrease in cash and cash equivalents
$(11,733)$(47,775)

Net cash provided by operating activities was $14.3 million for the nine months ended September 30, 2024, compared to net cash used in operating activities of $47.8 million for the nine months ended September 30, 2023. The increase in net cash provided by operating activities is primarily due to an increase in cash receipts from sales of LUPKYNIS and cash receipts from Otsuka, coupled with a reduction in operating expenses year over year, as a result of the restructuring in the first quarter of 2024. See "Total Revenue" above for further discussion regarding our increased sales of LUPKYNIS.
Cash provided by investing activities was $39 thousand during the nine months ended September 30, 2024, compared to net cash used of $0.4 million during the nine months ended September 30, 2023. The increase in cash provided by investing activities was primarily related to the timing of purchases and proceeds of investments and an upfront capital expenditure payment for the monoplant in 2023.
Cash used in financing activities was $26.0 million during the nine months ended September 30, 2024, compared to cash provided by financing activities of $0.4 million during the nine months ended September 30, 2023. The decrease was primarily due to share repurchases, which began in February 2024, and quarterly lease payments for our monoplant finance lease, which commenced during the third quarter of 2023.
Share Repurchase Program
In February 2024, the Board approved a share repurchase program of up to $150 million of our common shares. On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program.
As of September 30, 2024, we had repurchased approximately 3.4 million of our common shares for $18.6 million (including transaction costs which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common shares and under Alberta law, the shares were cancelled and not reissued.
Off‑Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off‑balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.
Contractual Obligations
There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023.
26

Item 3. Quantitative and Qualitative Disclosures About Market Risks
Our activities can expose us to market risks which include interest rate risk, foreign currency risk, inflation risk and credit risk. Risk management is carried out by management under policies approved by the Board, with oversight provided by the Audit Committee of the Board. Our overall risk management program seeks to minimize adverse effects on our financial performance.
Interest Rate Risk
Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct
operations on a day-to-day basis. As of September 30, 2024, our investment portfolio includes cash, cash equivalents, restricted cash, and investments of $348.7 million that earn interest at various rates. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. Our investments held during the year were comprised of highly rated instruments such as certificates of deposits, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities. As of September 30, 2024, these instruments primarily have a maturity of less than a year.

As of September 30, 2024, a hypothetical decrease of 100 basis points on the interest rates of our investments would result annually in approximately $3.1 million less interest in our portfolio. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio, due to the short-term nature of the investments and our current ability to hold these investments to maturity.

Accounts receivable, accounts payable and accrued liabilities bear no interest unless payments are not received timely. We do not believe that our results of operations or cash flows would be affected to a significant degree by a sudden change in market interest rates relative to our investment portfolio.

Foreign Currency Risk

We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Swiss franc, Canadian dollar and Great Britain Pound, which could affect our operating and financial results.

As of September 30, 2024, we had an $80.7 million finance lease liability on our balance sheet related to the monoplant. An assumed 10% fluctuation in the Swiss franc would have an approximate $8.1 million fluctuation in the valuation of the lease liability.

There were no other foreign currency fluctuations that would have had a material impact on our financial condition or results of operations as of September 30, 2024.

Inflation Risk

Inflation has been volatile in recent periods and may continue to be volatile in the future. Inflation generally affects us by increasing our cost of labor, commercial support, manufacturing and clinical trial expenditures. In addition, inflation also impacts our government and payer rebates as it pertains to the consumer price index (CPI) penalty. Our investment portfolio may experience the risk of realized losses on our investments if we were to sell before maturity due to the market volatility caused by increased interest rates.

Credit Risk

Our exposure to credit risk generally consists of cash and cash equivalents, investments and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions and invest the excess cash in highly rated investments. It is the
Company's intent for these investments to have an overall rating of A-1, or higher, by Standard & Poor’s, or an equivalent rating by Moody’s or Fitch. Our investment policy limits investments to certain types of debt and money market instruments issued by institutions primarily with investment grade credit ratings and places restriction on maturities and concentrations by asset class and issuer.

We are subject to credit risk in connection with our accounts receivable due from our two main specialty pharmacies for U.S. commercial sales, specialty distributor and collaboration partnership with Otsuka which accounted for the majority of our accounts receivable, net balances as of September 30, 2024. We monitor economic conditions, including the creditworthiness of
27

our customers and collaboration partner. We regularly communicate with our customers regarding the status of receivable balances and have not experienced and issues with collectability. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms range from 30 to 45 days. During the quarter ended September 30, 2024, we did not recognize any allowance for credit losses related to credit risk for our customers or write any amounts off.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of September 30, 2024, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
28

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. For further discussion, refer to Note 18, Commitments and Contingencies.
Other than as set out below, there are no material developments to report in respect of the litigation described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
On April 15, 2022, a purported shareholder class action complaint, Ortmann v. Aurinia Pharmaceuticals, Inc. et al., case no. 1:22-cv-02185, was filed in the United States District Court for the Eastern District of New York (Eastern District of New York), naming the Company and certain of its officers as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its financial guidance and commercial prospects in violation of certain federal securities laws. The plaintiff sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. On June 2, 2022, the case was transferred from the Eastern District of New York to the United States District Court for the District of Maryland. On February 20, 2023, the Court appointed a lead plaintiff and approved lead plaintiff’s selection of lead counsel. On May 22, 2023, the lead plaintiff filed its amended complaint. On October 20, 2023, the Company filed a motion to dismiss the amended complaint (the "Motion to Dismiss"). On December 8, 2023, the lead plaintiff filed its opposition to the Motion to Dismiss. On January 12, 2024, the Company filed its reply in support of the Motion to Dismiss. On August 13, 2024, the Court entered an order granting the Motion to Dismiss, with prejudice. The lead plaintiff did not file a motion for reconsideration or appeal the Court's order, and as such the action is dismissed in its entirety.
Item 1A. Risk Factors.
Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above, other than as set out below. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.
Aurinia's restructuring program and associated organizational changes may not adequately reduce its operating costs or improve operating margins, may lead to additional workforce attrition, and may cause operational disruptions, and there can be no assurance that Aurinia will realize the anticipated benefits of the restructuring program.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS growth and the rapid development of AUR200. This restructuring will result in a workforce reduction of approximately 45% and anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers.

The estimates of charges and expenditures, and the associated annual cost savings, Aurinia expects to incur in connection with the restructuring program, and timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and Aurinia may incur costs that are greater, or recognize lower annual cost savings, than Aurinia currently anticipates in connection with the restructuring program.

The restructuring program may yield unintended consequences, such as the loss of institutional knowledge and expertise, employee attrition beyond Aurinia's intended reduction in force, a reduction in morale among Aurinia's remaining employees, greater than anticipated costs incurred in connection with implementing the restructuring program, and the risks that Aurinia may not achieve the anticipated benefits from the restructuring program to the extent or as quickly as Aurinia anticipates, if at all, all of which may materially adversely affect Aurinia's results of operations or financial condition. These restructuring initiatives could place substantial demands on Aurinia's management and employees, which could lead to the diversion of management’s and employees’ attention from other business priorities. In addition, while certain positions are being eliminated in connection with the restructuring program, many functions necessary to Aurinia's reduced operations remain, and Aurinia may be unsuccessful in distributing the duties and obligations of departed employees among its remaining employees or to
29

external service providers, which could result in disruptions to Aurinia's operations. Aurinia may also discover that the workforce reduction and other restructuring efforts will make it difficult for Aurinia to pursue new opportunities and initiatives and require Aurinia to hire qualified replacement personnel, which may require Aurinia to incur additional and unanticipated costs and expenses. Aurinia may further discover that, despite the implementation of its restructuring program, Aurinia may require additional capital to continue expanding its business, and Aurinia may not be able to obtain such capital on acceptable terms, if at all. Aurinia's failure to successfully accomplish any of the above activities and goals may have a material adverse impact on its business, financial condition and results of operations.

Additionally, the workforce reduction Aurinia will implement as part of the restructuring program may negatively impact its ability to attract, integrate, retain and motivate highly qualified employees, and may harm Aurinia's reputation with current or prospective employees.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Purchases of Equity Securities
The following table summarizes the common share activity of our repurchased shares under our share repurchase program announced on February 15, 2024. Refer to Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" for further details of the share repurchase program.
Period
Total number of shares purchased
Average price paid per share in $
Total number of shares purchased as part of publicly announced program
Approximate dollar value of shares that may yet be purchased under program
(in thousands)(1)(2)
2/21/2024-3/21/2024
1,732,787$5.771,732,787$140,000
3/22/2024-3/28/2024
640,587$4.98640,587$136,809
4/1/2024-4/30/2024
1,049,556$4.931,049,556$131,638
5/1/2024-5/31/2024
891$4.99891$131,633
Total
3,423,8213,423,821
(1)The approximate value of shares that may yet be purchased under the program does not include commissions that may be paid to brokers in connection with such purchases.
(2)The approximate dollar value of shares that may be purchased under the program may differ from time to time from the value set out in the table above, as the Company is limited in how much it may repurchase both by the maximum dollar value of the program established by the Board, and also the maximum number of shares that may be repurchased in any 12 month period is limited by the Exemptive Relief (which may produce a lower maximum dollar value depending on the prices that common shares are repurchased under the program). As of September 30, 2024, the maximum dollar value would be approximately $131.6 million.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
30

Item 6. Exhibits.
The following exhibits are filed as part of this report:
Exhibit
Number		Description
3.1
3.2
31.1*
31.2*
32.1**
32.2**
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.
**Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

31

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AURINIA PHARMACEUTICALS INC.
November 6, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer, Director
(Principal Executive Officer)
November 6, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)
32

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Peter Greenleaf, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 6, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)


Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph Miller, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 6, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)


Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 6, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)


Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 6, 2024By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

v3.24.3
COVER - shares
 9 Months Ended
Sep. 30, 2024
Nov. 06, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-36421  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Address, Address Line One #140, 14315 - 118 Avenue  
Entity Address, City or Town Edmonton  
Entity Address, State or Province AB  
Entity Address, Postal Zip Code T5L 4S6  
Entity Tax Identification Number 98-1231763  
City Area Code (250)  
Local Phone Number 744-2487  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   143,179,269
Title of 12(b) Security Common shares, no par value  
Trading Symbol AUPH  
Security Exchange Name NASDAQ  
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001600620  
Current Fiscal Year End Date --12-31  
v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash, cash equivalents, and restricted cash $ 37,142 $ 48,875
Short-term investments 311,605 301,614
Accounts receivable, net 36,483 24,089
Inventories, net 38,714 39,705
Prepaid expenses and deposits 13,815 9,486
Other current assets 2,700 1,031
Total current assets 440,459 424,800
Non-current assets    
Long-term investments 0 201
Other non-current assets 868 1,517
Property and equipment, net 2,887 3,354
Acquired intellectual property and other intangible assets, net 4,509 4,977
Finance right-of-use assets, net 96,459 108,715
Operating right-of-use assets, net 4,179 4,498
Total assets 549,361 548,062
Current liabilities    
Accounts payable and accrued liabilities 56,770 54,389
Deferred revenue 4,304 4,813
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively) 1,590 2,388
Finance lease liabilities 14,927 14,609
Operating lease liabilities 1,018 989
Total current liabilities 78,609 77,188
Non-current liabilities    
Finance lease liabilities 65,955 75,479
Operating lease liabilities 5,951 6,530
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively) 10,844 10,911
Total liabilities 161,359 170,108
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY    
Common shares - no par value, unlimited shares authorized, 143,109 and 143,833 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 1,206,613 1,200,218
Additional paid-in capital 119,773 120,788
Accumulated other comprehensive loss (385) (730)
Accumulated deficit (937,999) (942,322)
Total shareholders' equity 388,002 377,954
Total liabilities and shareholders' equity $ 549,361 $ 548,062
v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively) $ 1,590 $ 2,388
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively) $ 10,844 $ 10,911
Common stock, par value (in usd per share) $ 0 $ 0
Common stock, issued (in shares) 143,109 143,833
Common stock, outstanding (in shares) 143,109 143,833
Related Party    
Other current liabilities (of which $0.8 million and $0.8 million at September 30, 2024 and December 31, 2023 is due to a related party, respectively) $ 800 $ 800
Deferred compensation and other non-current liabilities (of which $7.0 million at September 30, 2024 and $7.6 million in December 31, 2023 is due to a related party, respectively) $ 7,000 $ 7,600
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue        
Total revenue, net $ 67,771 $ 54,515 $ 175,266 $ 130,418
Operating expenses        
Cost of sales 6,035 6,769 22,696 8,753
Selling, general and administrative 42,367 47,759 134,996 144,964
Research and development 3,047 13,605 12,678 39,413
Restructuring expenses 0 0 7,755 0
Other expense (income), net 4,574 2,645 159 (695)
Total cost of sales and operating expenses 56,023 70,778 178,284 192,435
Income (Loss) from operations 11,748 (16,263) (3,018) (62,017)
Interest Expense, Nonoperating (1,208) (1,400) (3,689) (1,465)
Interest income 4,267 4,514 12,982 12,429
Net income (loss) before income taxes 14,807 (13,149) 6,275 (51,053)
Income tax expense 457 298 1,952 92
Net income (loss) 14,350 (13,447) 4,323 (51,145)
Other comprehensive (loss) gain:        
Unrealized gain on available-for-sale securities, net of tax of nil 474 73 345 114
Comprehensive income (loss) $ 14,824 $ (13,374) $ 4,668 $ (51,031)
Net income (loss) per share:        
Basic (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Diluted (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Weighted-average common shares outstanding:        
Basic (in shares) 143,051 142,847 143,353 143,085
Diluted (in shares) 145,651 142,847 145,010 143,085
Product revenue, net        
Revenue        
Total revenue, net $ 55,503 $ 40,781 $ 158,604 $ 116,218
License, collaboration, and royalty revenue        
Revenue        
Total revenue, net $ 12,268 $ 13,734 $ 16,662 $ 14,200
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Unrealized gain (loss) on available-for-sale securities, net of tax $ 0 $ 0 $ 0 $ 0
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Shares
Additional paid in capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2022   142,268      
Beginning Balance at Dec. 31, 2022 $ 405,435 $ 1,185,309 $ 85,489 $ (1,061) $ (864,302)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   1,127      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 3,024 $ 11,141 (8,117)    
Issuance of common shares in conjunction with ESPP program (in shares)   210      
Issuance of common shares in conjunction with ESPP program 906 $ 2,110 (1,204)    
Share-based compensation 33,543   33,543    
Unrealized gain on available-for-sale securities, net 114     114  
Net income (loss) (51,145)       (51,145)
Ending Balance (in shares) at Sep. 30, 2023   143,605      
Ending Balance at Sep. 30, 2023 391,877 $ 1,198,560 109,711 (947) (915,447)
Beginning Balance (in shares) at Jun. 30, 2023   143,369      
Beginning Balance at Jun. 30, 2023 392,292 $ 1,196,480 98,832 (1,020) (902,000)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   236      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 1,151 $ 2,080 (929)    
Share-based compensation 11,808   11,808    
Unrealized gain on available-for-sale securities, net 73     73  
Net income (loss) (13,447)       (13,447)
Ending Balance (in shares) at Sep. 30, 2023   143,605      
Ending Balance at Sep. 30, 2023 $ 391,877 $ 1,198,560 109,711 (947) (915,447)
Beginning Balance (in shares) at Dec. 31, 2023 143,833 143,833      
Beginning Balance at Dec. 31, 2023 $ 377,954 $ 1,200,218 120,788 (730) (942,322)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares) 125 2,548      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units $ 646 $ 23,966 (23,320)    
Shares repurchased and cancelled, inclusive of transaction costs (in shares)   (3,424)      
Shares repurchased and cancelled, inclusive of transaction costs (18,619) $ (18,619)      
Issuance of common shares in conjunction with ESPP program (in shares)   152      
Issuance of common shares in conjunction with ESPP program 703 $ 1,048 (345)    
Share-based compensation 22,650   22,650    
Unrealized gain on available-for-sale securities, net 345     345  
Net income (loss) $ 4,323       4,323
Ending Balance (in shares) at Sep. 30, 2024 143,109 143,109      
Ending Balance at Sep. 30, 2024 $ 388,002 $ 1,206,613 119,773 (385) (937,999)
Beginning Balance (in shares) at Jun. 30, 2024   142,984      
Beginning Balance at Jun. 30, 2024 364,616 $ 1,205,554 112,270 (859) (952,349)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units (in shares)   125      
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units 235 $ 1,059 (824)    
Share-based compensation 8,327   8,327    
Unrealized gain on available-for-sale securities, net 474     474  
Net income (loss) $ 14,350       14,350
Ending Balance (in shares) at Sep. 30, 2024 143,109 143,109      
Ending Balance at Sep. 30, 2024 $ 388,002 $ 1,206,613 $ 119,773 $ (385) $ (937,999)
v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net income (loss) $ 4,323 $ (51,145)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 14,583 6,698
Net amortization of premiums and discounts on short-term investments (9,752) (8,836)
Share-based compensation expense 22,650 33,543
Foreign exchange on finance lease liability (718) (1,335)
Other, net 220 (1,659)
Net changes in operating assets and liabilities    
Accounts receivable, net (12,394) (24,463)
Inventories, net 991 (8,984)
Prepaid expenses and other current assets (6,001) (2,889)
Non-current operating assets (12) (16)
Accounts payable, accrued and other liabilities 934 11,812
Operating lease liabilities (550) (499)
Net cash provided by (used in) operating activities 14,274 (47,773)
Cash flows from investing activities    
Purchase of investments (461,140) (379,213)
Proceeds from investments 461,448 391,287
Upfront lease payment (44) (11,864)
Purchase of property and equipment 0 (419)
Capitalized patent costs (225) (240)
Net cash provided by (used in) investing activities 39 (449)
Cash flows from financing activities    
Repurchase of common shares (18,435) 0
Principal portion of finance lease payments (8,959) (3,482)
Proceeds from exercise of stock options and employee share purchase plan 1,348 3,929
Cash (used in) provided by financing activities (26,046) 447
Net decrease in cash, cash equivalents, and restricted cash (11,733) (47,775)
Cash, cash equivalents, and restricted cash, beginning of period 48,875 94,172
Cash, cash equivalents, and restricted cash, end of period 37,142 46,397
Supplemental cash flow information    
Cash received for interest 2,803 3,559
Cash paid for income taxes (1,459) (339)
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets    
Cash, cash equivalents 36,630 45,557
Restricted cash 512 840
Total cash, cash equivalents, and restricted cash $ 37,142 $ 46,397
v3.24.3
Organization and Description of Business
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories).
On February 15, 2024, the Company announced the conclusion of its previously announced strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25% and discontinued its AUR300 research and development program. For further discussion, refer to Note 19, Restructuring.
On November 7, 2024, Aurinia announced it was implementing a strategic restructuring to sharpen the Company's focus on continued LUPKYNIS® growth and the rapid development of AUR200. This restructuring will result in a workforce reduction of approximately 45% and Aurinia anticipates a one-time restructuring charge in the fourth quarter of 2024 of approximately $15 to $19 million and will focus the Company’s LUPKYNIS commercial strategy on the highest growth drivers.
The Company is also developing its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). On September 5, 2024, the Company announced the first participant has been dosed in a Phase 1 single ascending dose (SAD) study of AUR200. The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025.
Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a United States commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH.
v3.24.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.
Significant Accounting Policies
The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, other than as stated below.
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories. Revenues from our two main customers represented approximately 49% and 38% of revenues for the nine months ended September 30, 2024. Revenues from our two main customers represented approximately 50% and 39% of revenues for the nine months ended September 30, 2023.
In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand for risk mitigation and supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables.
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As
of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses: Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares: The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
v3.24.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company's financial instruments consist primarily of cash, cash equivalents, restricted cash, investments, accounts receivable, accounts payable, and accrued liabilities. The carrying value of accounts receivable, accounts payable, and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such
assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:
September 30, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds— 601 — 601 
Commercial paper— 2,028 — 2,028 
Treasury bills— 196,471 — 196,471 
Treasury bonds— 112,505 — 112,505 
Total financial assets$37,142 $311,605 $— $348,747 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
The Company's Level 1 instruments include cash, cash equivalents, and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At September 30, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 7 months for both periods. The Company's policy is for these investments to have an overall rating of A-1, or higher, by Standard & Poor's, or an equivalent rating by Moody’s or Fitch.
No credit loss allowance was recorded as of September 30, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted.
Refer to Note 4, Cash, Cash Equivalents, Restricted Cash, and Investments, for the carrying amount and related unrealized gains (losses) by type of investment.
v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Investments Cash, Cash Equivalents, Restricted Cash, and Investments
As of September 30, 2024, and December 31, 2023, the Company had $348.7 million and $350.7 million, respectively of cash, cash equivalents, restricted cash, and investments summarized below. As of September 30, 2024, and December 31, 2023, $311.6 million and $301.8 million were available-for-sale debt securities which are carried at fair market value.
September 30, 2024
(in thousands)Amortized CostUnrealized Gains
Unrealized Losses
Estimated Fair Value
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds599 2 — 601 
Commercial paper2,028 — — 2,028 
Treasury bills196,311 160 — 196,471 
Treasury bonds112,246 259 — 112,505 
Total cash, cash equivalents, restricted cash, and short-term investments
348,326 421 — 348,747 
Total long-term investment corporate bond— — — — 
Total cash, cash equivalents, restricted cash, and investments
$348,326 $421 $— $348,747 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash, and short-term investments
350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash, and investments
$350,616 $75 $(1)$350,690 

As of September 30, 2024, and December 31, 2023, accrued interest receivable from investments was $0.5 million and $0.7 million, respectively. During the three and nine months ended September 30, 2024, the Company had $0.5 million and $0.3 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. During the three and nine months ended September 30, 2023, the Company had $0.1 million and $0.1 million of unrealized gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive income (loss) on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized gains on investments at September 30, 2024, were temporary in nature. Realized gains or losses were immaterial during the three and nine months ended September 30, 2024, and 2023.
The Company's short-term investments as of September 30, 2024 mature at various dates through August 2025.
v3.24.3
Inventories, net
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventories, net Inventories, net
Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of
regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers.

The Company assesses recoverability of inventory each reporting period to determine if any write-down to net realizable value is necessary. As of September 30, 2024, and December 31, 2023, Aurinia recorded reserves of finished goods inventories of nil and $0.8 million, respectively, which were primarily related to potential inventory obsolescence.

The components of inventory, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process34,990 37,376 
Finished goods, net of reserve2,022 583 
Total inventories, net$38,714 $39,705 
v3.24.3
Prepaid Expenses and Deposits
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Deposits Prepaid Expenses and Deposits
Prepaid expenses are as follows:

(in thousands)September 30, 2024December 31, 2023
Prepaid assets$7,730 $6,892 
Prepaid deposits4,189 1,345 
Prepaid insurance1,896 1,249 
Total prepaid expenses and deposits
$13,815 $9,486 
v3.24.3
Intangible Assets
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$2,073 $(1,354)$719 
Acquired intellectual property and reacquired rights15,126 (11,336)3,790 
Internal-use software implementation costs2,873 (2,873)— 
$20,072 $(15,563)$4,509 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
Amortization expense for the three months ended September 30, 2024, and 2023, was approximately $0.2 million and $0.5 million, respectively. Amortization for the nine months ended September 30, 2024, and 2023, was approximately $0.7 million and $1.4 million, respectively.
v3.24.3
Property and Equipment, net
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,377)(1,910)
Property and equipment, net$2,887 $3,354 
v3.24.3
Lease Obligations
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Lease Obligations Lease Obligations
The Company has the following lease obligations:
Rockville, Maryland
During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2024, the Company had a right-of-use (ROU) asset of $4.1 million and lease liability of $6.8 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right-of-use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability.
When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at the lease commencement date on March 12, 2020. The incremental borrowing rate applied to the lease liability was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position.
For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position.
The operating lease costs for all leases for the three and nine months ended September 30, 2024, and September 30, 2023, were $0.2 million and $0.6 million, respectively.
Monoplant
At lease inception, the Company recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease. As the monoplant finance lease is denominated in Swiss francs, the company incurs unrealized and realized foreign exchange gains and losses each reporting period related to the valuation of the lease liability and timing of lease payments.

As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $95.6 million and $80.7 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three and nine months ended September 30, 2024, ROU amortization was $4.4 million and $13.1 million, respectively. For the three and nine months ended September 30, 2024, interest expense was $1.2 million and $3.7 million, respectively.
Beinheim
The Company entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that commenced operations during June 2024 with a lease term of seven years. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease.
As of September 30, 2024, the ROU asset, net and corresponding lease liability balance were $0.8 million and $0.1 million, respectively.
The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:
As of September 30, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases6.95.27%
Finance lease
5.56.19%
Supplemental cash flow information related to leases are as follows:
Nine Months Ended
September 30,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows for finance leases
$(8,959)$(3,482)
Operating cash flows for finance leases
$(3,354)$(718)
Operating cash flows for operating leases
$(831)$(805)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations
$96,459 $113,069 
Finance lease liability arising from obtaining right-of-use assets
$80,882 $85,521 
Future maturities of lease liabilities as of September 30, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$4,295 $283 
202517,203 1,141 
202617,204 1,169 
202717,204 1,198 
202817,205 1,227 
Thereafter21,554 3,302 
Total lease payments
94,665 8,320 
Less: imputed interest
(13,783)(1,351)
Total
$80,882 $6,969 
v3.24.3
Accounts Payable and Accrued Liabilities
 9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2024December 31, 2023
Commercial accruals
$25,523 $16,216 
Employee accruals
14,180 22,486 
Trade payables
8,878 4,327 
Other accrued liabilities
4,672 5,190 
Accrued R&D projects
2,331 5,503 
Income taxes payable
1,007 667 
Restructuring accruals
179 — 
Total accounts payable and accrued liabilities$56,770 $54,389 
v3.24.3
Deferred Compensation and Other Non-current Liabilities
 9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Deferred Compensation and Other Non-current Liabilities Deferred Compensation and Other Non-current Liabilities
The Company recorded other non-current liabilities of $10.8 million and $10.9 million as of September 30, 2024, and December 31, 2023, respectively. The balance for both periods primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors (the Board) on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions.
v3.24.3
License and Collaboration Agreements
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
License and Collaboration Agreements License and Collaboration Agreements
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023.

As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $50.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with
additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates.
On September 24, 2024, the Company announced that the Japanese Ministry of Health, Labour, and Welfare has approved LUPKYNIS, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat LN. As part of the December 2020 agreement with Otsuka, the Company is eligible to receive a payment of $10.0 million U.S. dollars upon approval in Japan along with low double-digit royalties on net sales once launched. As a result, the $10.0 million milestone was recognized as collaboration revenue in the quarter.
For the three and nine months ended September 30, 2024, the Company recognized $12.3 million and $16.7 million, respectively of license, collaboration, and royalty revenue from services provided under the Otsuka agreement. For the three and nine months ended September 30, 2023, the Company recognized $12.7 million and $13.2 million, respectively.
v3.24.3
Shareholder's Equity
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Shareholder's Equity Shareholder's Equity
On February 15, 2024, Aurinia announced that the Board had approved a share repurchase program of up to $150 million common shares of the Company, affirming its confidence in the Company's growth prospects.

On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws.
As of September 30, 2024, the Company had repurchased approximately 3.4 million of Aurinia's common shares for $18.6 million (including transaction costs, which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common shares and under Alberta law, the shares were cancelled and not reissued.
v3.24.3
Net Income (Loss) per Common Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net Income (Loss) per Common Share Net Income (Loss) per Common Share
Basic and diluted net loss per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. For the periods in a loss position, diluted net loss per share is the same as basic net loss per share. The treasury stock method is used to determine the dilutive effect of the Company's stock options, RSUs, performance awards and ESPP. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three Months Ended
 September 30,
Nine Months Ended
September 30,
(in thousands, except per share data)2024202320242023
Numerator:
Net income (loss) used for the calculation of basic and diluted EPS
$14,350 $(13,447)$4,323 $(51,145)
Denominator:
Weighted-average common shares outstanding, basic
143,051 142,847 143,353 143,085 
Effect of dilutive shares:
Stock options, RSUs, performance awards and ESPP
2,600 — 1,657 — 
Weighted-average diluted common shares outstanding, diluted
145,651 142,847 145,010 143,085 
Net income (loss) per share, basic
$0.10 $(0.09)0.03 (0.36)
Net income (loss) per share, diluted
$0.10 $(0.09)$0.03 $(0.36)
The Company did not include certain shares issuable under share-based compensation plans because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.
v3.24.3
Share-based Compensation
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-based Compensation Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of September 30, 2024, 0.9 million shares have been purchased under the ESPP.
In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan.
Stock Options
The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent
remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior.
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.08 %3.92 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.0 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$3.82 $5.94 
The following table summarizes the option award activity for the nine months ended September 30, 2024:

September 30, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted325 5.89 
Exercised(125)5.18 
Forfeited or cancelled
(2,006)12.81 
Outstanding - September 30, 2024
9,750 $10.09 
Restricted Stock Units and Performance Awards
The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant.
The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:
September 30, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,663 6.89 
Vested(2,422)9.50 
Forfeited(1,673)8.99 
Unvested balance - September 30, 2024
8,375 $7.96 
Share-based Compensation Expense
The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Research and development$306 $1,975 $(1,773)$5,679 
Selling, general and administrative7,812 9,560 23,427 26,969 
Capitalized under inventories209 273 996 895 
Share-based compensation expense$8,327 $11,808 $22,650 $33,543 
As of September 30, 2024, there was $25.7 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.3 years.
v3.24.3
Income Taxes
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The effective tax rates for the three and nine months ended September 30, 2024, and September 30, 2023, differed from the Canadian statutory rate applied to income or losses before income taxes primarily as a result of the mix of income, losses and valuation allowances.

The Company recognized an income tax expense of approximately $0.5 million and $2.0 million for the three and nine months ended September 30, 2024, respectively. The Company recognized an income tax expense of approximately $0.3 million and $0.1 million for the three and nine months ended September 30, 2023, respectively. The income tax expense recognized for these periods is a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.
v3.24.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board on September 21, 2023. As of September 30, 2024, the Company had $0.8 million and $7.0 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of September 30, 2024, and December 31, 2023, the Company made payments of $0.4 million and $0.1 million, respectively for each period as a related party for the deferred compensation.
v3.24.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. Other than as described under Part II, Item I, the Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Other Funding Commitments
In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company.
v3.24.3
Restructuring
 9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program.
As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:
(in thousands)
Nine Months Ended September 30, 2024
Employee severance and one time benefits
$6,075 
Contract terminations
1,105 
Other costs
575 
Total
$7,755 
v3.24.3
Subsequent Events
 9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Effective November 7, 2024, Aurinia appointed Craig Johnson to the Board. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry.
The Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.
v3.24.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of September 30, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods.
Principles of Consolidation
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment.
These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date the assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other expense (income), net.
Product Revenues
Product Revenues
We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor, and semi-finished product directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products. Revenues from product sales are recognized when the customer obtains control of the Company's product, which occurs upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer).
The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available.
Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed to patients. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to its specialty pharmacies that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of September 30, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Major Customers Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration, and manufacturing services revenue in the Otsuka Territories.
Accounts Receivable, net
Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As
of September 30, 2024, and December 31, 2023, accounts receivable, net are $36.5 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the accounts receivable. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of September 30, 2024, and December 31, 2023.
Share-Based Compensation
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation, which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Restructuring Expenses
Restructuring Expenses: Restructuring expenses consist primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations, one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time.
Common Shares
Common Shares: The Company’s shares have no par value or stated value and therefore, upon issuance or repurchase of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company is currently assessing the potential impact this ASU may have on the consolidated financial statements.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements.
v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table summarizes the financial assets (cash, cash equivalents, restricted cash, and investments) measured at fair value on a recurring basis:
September 30, 2024
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds— 601 — 601 
Commercial paper— 2,028 — 2,028 
Treasury bills— 196,471 — 196,471 
Treasury bonds— 112,505 — 112,505 
Total financial assets$37,142 $311,605 $— $348,747 
December 31, 2023
(in thousands)Level 1Level 2Level 3Total
Financial assets:
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds— 33,781 — 33,781 
Commercial paper— 39,304 — 39,304 
Treasury bills— 122,806 — 122,806 
Treasury bonds— 105,924 — 105,924 
Total financial assets$48,875 $301,815 $— $350,690 
v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments (Tables)
 9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash, Cash Equivalents, Restricted Cash and Investments
September 30, 2024
(in thousands)Amortized CostUnrealized Gains
Unrealized Losses
Estimated Fair Value
Cash, cash equivalents, and restricted cash
$37,142 $— $— $37,142 
Corporate bonds599 2 — 601 
Commercial paper2,028 — — 2,028 
Treasury bills196,311 160 — 196,471 
Treasury bonds112,246 259 — 112,505 
Total cash, cash equivalents, restricted cash, and short-term investments
348,326 421 — 348,747 
Total long-term investment corporate bond— — — — 
Total cash, cash equivalents, restricted cash, and investments
$348,326 $421 $— $348,747 
December 31, 2023
(in thousands)Amortized CostUnrealized GainsUnrealized LossesEstimated Fair Value
Cash, cash equivalents, and restricted cash
$48,875 $— $— $48,875 
Corporate bonds33,576 4 — 33,580 
Commercial paper39,305 — (1)39,304 
Treasury bills122,757 49 — 122,806 
Treasury bonds105,903 21 — 105,924 
Total cash, cash equivalents, restricted cash, and short-term investments
350,416 74 (1)350,489 
Total long-term investment corporate bond
200 1 — 201 
Total cash, cash equivalents, restricted cash, and investments
$350,616 $75 $(1)$350,690 
v3.24.3
Inventories, net (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
The components of inventory, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Raw materials$1,702 $1,746 
Work in process34,990 37,376 
Finished goods, net of reserve2,022 583 
Total inventories, net$38,714 $39,705 
v3.24.3
Prepaid Expenses and Deposits (Tables)
 9 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Deposits
Prepaid expenses are as follows:

(in thousands)September 30, 2024December 31, 2023
Prepaid assets$7,730 $6,892 
Prepaid deposits4,189 1,345 
Prepaid insurance1,896 1,249 
Total prepaid expenses and deposits
$13,815 $9,486 
v3.24.3
Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2024
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$2,073 $(1,354)$719 
Acquired intellectual property and reacquired rights15,126 (11,336)3,790 
Internal-use software implementation costs2,873 (2,873)— 
$20,072 $(15,563)$4,509 
December 31, 2023
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,847 $(1,297)$550 
Acquired intellectual property and reacquired rights15,126 (10,737)4,389 
Internal-use software implementation costs2,873 (2,835)38 
$19,846 $(14,869)$4,977 
v3.24.3
Property and Equipment, net (Tables)
 9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment, net are as follows:
(in thousands)September 30, 2024December 31, 2023
Leasehold improvements$3,243 $3,243 
Office equipment631 631 
Furniture1,155 1,155 
Computer equipment235 235 
5,2645,264
Less accumulated depreciation(2,377)(1,910)
Property and equipment, net$2,887 $3,354 
v3.24.3
Lease Obligations (Tables)
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Schedule of Lease Cost
The following table represents the weighted-average remaining lease terms and discount rates as of September 30, 2024:
As of September 30, 2024
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases6.95.27%
Finance lease
5.56.19%
Supplemental cash flow information related to leases are as follows:
Nine Months Ended
September 30,
20242023
(in thousands)
Cash paid for amounts included in the measurement of lease liabilities
Financing cash flows for finance leases
$(8,959)$(3,482)
Operating cash flows for finance leases
$(3,354)$(718)
Operating cash flows for operating leases
$(831)$(805)
Supplemental disclosure of noncash transactions
Finance right-of-use asset obtained in exchange for lease obligations
$96,459 $113,069 
Finance lease liability arising from obtaining right-of-use assets
$80,882 $85,521 
Schedule of Maturities of Lease Liabilities
Future maturities of lease liabilities as of September 30, 2024 are as follows:
(in thousands)Finance Lease PaymentsOperating Lease Payments
Remainder of 2024$4,295 $283 
202517,203 1,141 
202617,204 1,169 
202717,204 1,198 
202817,205 1,227 
Thereafter21,554 3,302 
Total lease payments
94,665 8,320 
Less: imputed interest
(13,783)(1,351)
Total
$80,882 $6,969 
v3.24.3
Accounts Payable and Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
Accounts payable and accrued liabilities are as follows:
(in thousands)September 30, 2024December 31, 2023
Commercial accruals
$25,523 $16,216 
Employee accruals
14,180 22,486 
Trade payables
8,878 4,327 
Other accrued liabilities
4,672 5,190 
Accrued R&D projects
2,331 5,503 
Income taxes payable
1,007 667 
Restructuring accruals
179 — 
Total accounts payable and accrued liabilities$56,770 $54,389 
v3.24.3
Net Income (Loss) per Common Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings (Loss) Per Share, Basic and Diluted The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three Months Ended
 September 30,
Nine Months Ended
September 30,
(in thousands, except per share data)2024202320242023
Numerator:
Net income (loss) used for the calculation of basic and diluted EPS
$14,350 $(13,447)$4,323 $(51,145)
Denominator:
Weighted-average common shares outstanding, basic
143,051 142,847 143,353 143,085 
Effect of dilutive shares:
Stock options, RSUs, performance awards and ESPP
2,600 — 1,657 — 
Weighted-average diluted common shares outstanding, diluted
145,651 142,847 145,010 143,085 
Net income (loss) per share, basic
$0.10 $(0.09)0.03 (0.36)
Net income (loss) per share, diluted
$0.10 $(0.09)$0.03 $(0.36)
v3.24.3
Share-based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award Valuation Assumptions
The following weighted average assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024, and September 30, 2023:
20242023
Annualized volatility77 %71 %
Risk-free interest rate4.08 %3.92 %
Expected life of options in years5.0 years5.0 years
Estimated forfeiture rate13.0 %12.7 %
Dividend rate0.0 %0.0%
Fair value per common share option$3.82 $5.94 
Schedule of Option Activity
The following table summarizes the option award activity for the nine months ended September 30, 2024:

September 30, 2024
Number of shares (in thousands)Weighted average exercise price $
Outstanding - December 31, 2023
11,556 $10.63 
Granted325 5.89 
Exercised(125)5.18 
Forfeited or cancelled
(2,006)12.81 
Outstanding - September 30, 2024
9,750 $10.09 
Schedule of Performance Shares Activity
The following table summarizes the RSU and PA activity for the nine months ended September 30, 2024:
September 30, 2024
Number of shares (in thousands)Weighted average fair value price $
Unvested balance, December 31, 2023
7,807 $9.29 
Granted4,663 6.89 
Vested(2,422)9.50 
Forfeited(1,673)8.99 
Unvested balance - September 30, 2024
8,375 $7.96 
Schedule of Allocation of Share-Based Payments
The Company recognized share-based compensation expense for the three and nine months ended September 30, 2024, and September 30, 2023, as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2024202320242023
Research and development$306 $1,975 $(1,773)$5,679 
Selling, general and administrative7,812 9,560 23,427 26,969 
Capitalized under inventories209 273 996 895 
Share-based compensation expense$8,327 $11,808 $22,650 $33,543 
v3.24.3
Restructuring (Tables)
 9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Related Costs
As of September 30, 2024, the restructuring expenses are included within operating expenses on the condensed consolidated statements of operations and comprehensive income (loss). For the three and nine months ended September 30, 2024, restructuring expenses were nil and $7.8 million, respectively. Restructuring expenses consisted of the following:
(in thousands)
Nine Months Ended September 30, 2024
Employee severance and one time benefits
$6,075 
Contract terminations
1,105 
Other costs
575 
Total
$7,755 
v3.24.3
Organization and Description of Business (Details) - USD ($)
$ in Millions
 3 Months Ended
Nov. 07, 2024
Dec. 31, 2024
Mar. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of positions eliminated, percent     25.00%
Employee severance and one time benefits | Strategic Restructuring Plan | Minimum | Forecast      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Restructuring charges   $ 15.0  
Employee severance and one time benefits | Strategic Restructuring Plan | Maximum | Forecast      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Restructuring charges   $ 19.0  
Employee severance and one time benefits | Strategic Restructuring Plan | Subsequent Event      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of positions eliminated, percent 45.00%    
v3.24.3
Summary of Significant Accounting Policies- Narrative (Details)
 9 Months Ended
Sep. 30, 2024
USD ($)
segment
Sep. 30, 2023
Dec. 31, 2023
USD ($)
Property, Plant and Equipment [Line Items]      
Number of operating segments | segment 1    
Number of customers | segment 2    
Accounts receivable, net | $ $ 36,483,000   $ 24,089,000
Allowance for doubtful accounts | $ $ 0   $ 0
Revenue Benchmark | Customer Concentration Risk | Major Customer One      
Property, Plant and Equipment [Line Items]      
Concentration risk (as percent) 49.00% 50.00%  
Revenue Benchmark | Customer Concentration Risk | Major Customer Two      
Property, Plant and Equipment [Line Items]      
Concentration risk (as percent) 38.00% 39.00%  
Minimum      
Property, Plant and Equipment [Line Items]      
Receivable standard credit terms (in days) 30 days    
Maximum      
Property, Plant and Equipment [Line Items]      
Receivable standard credit terms (in days) 45 days    
v3.24.3
Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Financial assets:    
Total financial assets $ 348,747 $ 350,690
Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets 37,142 48,875
Corporate bonds    
Financial assets:    
Total financial assets 601 33,781
Commercial paper    
Financial assets:    
Total financial assets 2,028 39,304
Treasury bills    
Financial assets:    
Total financial assets 196,471 122,806
Treasury bonds    
Financial assets:    
Total financial assets 112,505 105,924
Level 1    
Financial assets:    
Total financial assets 37,142 48,875
Level 1 | Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets 37,142 48,875
Level 1 | Corporate bonds    
Financial assets:    
Total financial assets 0 0
Level 1 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 1 | Treasury bills    
Financial assets:    
Total financial assets 0 0
Level 1 | Treasury bonds    
Financial assets:    
Total financial assets 0 0
Level 2    
Financial assets:    
Total financial assets $ 311,605 $ 301,815
Derivative, average remaining maturity (in months) 7 months 7 months
Level 2 | Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets $ 0 $ 0
Level 2 | Corporate bonds    
Financial assets:    
Total financial assets 601 33,781
Level 2 | Commercial paper    
Financial assets:    
Total financial assets 2,028 39,304
Level 2 | Treasury bills    
Financial assets:    
Total financial assets 196,471 122,806
Level 2 | Treasury bonds    
Financial assets:    
Total financial assets 112,505 105,924
Level 3    
Financial assets:    
Total financial assets 0 0
Level 3 | Cash, cash equivalents, and restricted cash    
Financial assets:    
Total financial assets 0 0
Level 3 | Corporate bonds    
Financial assets:    
Total financial assets 0 0
Level 3 | Commercial paper    
Financial assets:    
Total financial assets 0 0
Level 3 | Treasury bills    
Financial assets:    
Total financial assets 0 0
Level 3 | Treasury bonds    
Financial assets:    
Total financial assets $ 0 $ 0
v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]          
Total cash, cash equivalents, restricted cash, and investments $ 348,700   $ 348,700   $ 350,690
Estimated Fair Value 311,600   311,600   301,800
Interest receivable 500   500   $ 700
Unrealized gain on available-for-sale securities $ 500 $ 100 $ 300 $ 100  
v3.24.3
Cash, Cash Equivalents, Restricted Cash and Investments - Schedule of Cash, Cash Equivalents, Restricted Cash and Investments (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Marketable Securities [Line Items]    
Amortized Cost $ 348,326 $ 350,416
Unrealized Gains 421 74
Unrealized Losses 0 1
Estimated Fair Value 311,600 301,800
Total cash, cash equivalents, restricted cash and investments, Amortized Cost 348,326 350,616
Total cash, cash equivalents, restricted cash and investments, unrealized gains 421 75
Total cash, cash equivalents, restricted cash and investments, unrealized losses 0 (1)
Total cash, cash equivalents, restricted cash, and investments 348,700 350,690
Cash, cash equivalents, restricted cash and investments 348,747 350,489
Cash, cash equivalents, and restricted cash    
Marketable Securities [Line Items]    
Amortized Cost 37,142 48,875
Unrealized Gains 0 0
Unrealized Losses 0 0
Estimated Fair Value 37,142 48,875
Corporate bonds    
Marketable Securities [Line Items]    
Amortized Cost 599 33,576
Unrealized Gains 2 4
Unrealized Losses 0 0
Estimated Fair Value 601 33,580
Commercial paper    
Marketable Securities [Line Items]    
Amortized Cost 2,028 39,305
Unrealized Gains 0 0
Unrealized Losses 0 1
Estimated Fair Value 2,028 39,304
Treasury bills    
Marketable Securities [Line Items]    
Amortized Cost 196,311 122,757
Unrealized Gains 160 49
Unrealized Losses 0 0
Estimated Fair Value 196,471 122,806
Treasury bonds    
Marketable Securities [Line Items]    
Amortized Cost 112,246 105,903
Unrealized Gains 259 21
Unrealized Losses 0 0
Estimated Fair Value 112,505 105,924
Total long-term investment corporate bond    
Marketable Securities [Line Items]    
Amortized Cost 0 200
Unrealized Gains 0 1
Unrealized Losses 0 0
Estimated Fair Value $ 0 $ 201
v3.24.3
Inventories, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods inventories $ 0 $ 800
Raw materials 1,702 1,746
Work in process 34,990 37,376
Finished goods, net of reserve 2,022 583
Total inventories, net $ 38,714 $ 39,705
v3.24.3
Prepaid Expenses and Deposits (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid assets $ 7,730 $ 6,892
Prepaid deposits 4,189 1,345
Prepaid insurance 1,896 1,249
Total prepaid expenses and deposits $ 13,815 $ 9,486
v3.24.3
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 20,072 $ 19,846
Accumulated Amortization (15,563) (14,869)
Net Carrying Amount 4,509 4,977
Patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,073 1,847
Accumulated Amortization (1,354) (1,297)
Net Carrying Amount 719 550
Acquired intellectual property and reacquired rights    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 15,126 15,126
Accumulated Amortization (11,336) (10,737)
Net Carrying Amount 3,790 4,389
Internal-use software implementation costs    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,873 2,873
Accumulated Amortization (2,873) (2,835)
Net Carrying Amount $ 0 $ 38
v3.24.3
Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 0.2 $ 0.5 $ 0.7 $ 1.4
v3.24.3
Property and Equipment, net (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 5,264 $ 5,264
Less accumulated depreciation (2,377) (1,910)
Property and equipment, net 2,887 3,354
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 3,243 3,243
Office equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 631 631
Furniture    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 1,155 1,155
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 235 $ 235
v3.24.3
Lease Obligations - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2020
ft²
extension_option
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Oct. 31, 2022
ft²
Mar. 12, 2020
Lessee, Lease, Description [Line Items]                  
Operating right-of-use assets, net   $ 4,179   $ 4,179   $ 4,498      
Operating lease liability   $ 6,969   $ 6,969          
Operating lease, weighted average discount rate   5.27%   5.27%          
Operating lease costs   $ 200 $ 200 $ 600 $ 600        
Finance right-of-use assets, net   96,459   96,459   108,715      
Finance lease, liability   $ 80,882   $ 80,882          
Finance lease, weighted average discount rate   6.19%   6.19%          
Rockville, Maryland                  
Lessee, Lease, Description [Line Items]                  
Area of property (in sqft) | ft² 30,531                
Remaining lease term (in years) 7 years                
Number of extension options (in years) | extension_option 2                
Lease extension term (in years) 5 years                
Lease term (in years) 11 years                
Operating right-of-use assets, net   $ 4,100   $ 4,100   4,500      
Operating lease liability   6,800   6,800   7,400      
Proceeds from tenant improvements           2,300      
Operating lease, weighted average discount rate                 5.20%
Edmonton, Alberta                  
Lessee, Lease, Description [Line Items]                  
Area of property (in sqft) | ft²               4,375  
Remaining lease term (in years)               6 years  
Lease extension term (in years)               5 years  
Monoplant                  
Lessee, Lease, Description [Line Items]                  
Finance right-of-use assets, net   95,600   95,600   108,700 $ 117,600    
Finance lease, liability   80,700   80,700   $ 90,100 $ 94,100    
Finance lease, weighted average discount rate             6.19%    
Finance lease, right-of-use asset, amortization   4,400   13,100          
Interest expense   1,200   3,700          
Beinheim                  
Lessee, Lease, Description [Line Items]                  
Finance right-of-use assets, net   800   800          
Finance lease, liability   $ 100   $ 100          
Finance lease, weighted average discount rate             6.19%    
Lease termination option term (in years) 7 years                
v3.24.3
Lease Obligations - Schedule of Lease Cost (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Leases [Abstract]    
Operating lease, weighted average remaining lease term (years) 6 years 10 months 24 days  
Operating lease, weighted average discount rate 5.27%  
Finance lease, operating lease, weighted average remaining lease term (years) 5 years 6 months  
Finance lease, weighted average discount rate 6.19%  
Cash paid for amounts included in the measurement of lease liabilities    
Financing cash flows for finance leases $ (8,959) $ (3,482)
Operating cash flows for finance leases (3,354) (718)
Operating cash flows for operating leases (831) (805)
Supplemental disclosure of noncash transactions    
Finance right-of-use asset obtained in exchange for lease obligations 96,459 113,069
Finance lease liability arising from obtaining right-of-use assets $ 80,882 $ 85,521
v3.24.3
Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Finance Lease Payments  
Remainder of 2024 $ 4,295
2025 17,203
2026 17,204
2027 17,204
2028 17,205
Thereafter 21,554
Total lease payments 94,665
Less: imputed interest (13,783)
Total 80,882
Operating Lease Payments  
Remainder of 2024 283
2025 1,141
2026 1,169
2027 1,198
2028 1,227
Thereafter 3,302
Total lease payments 8,320
Less: imputed interest (1,351)
Total $ 6,969
v3.24.3
Accounts Payable and Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Commercial accruals $ 25,523 $ 16,216
Employee accruals 14,180 22,486
Trade payables 8,878 4,327
Other accrued liabilities 4,672 5,190
Accrued R&D projects 2,331 5,503
Income taxes payable 1,007 667
Restructuring accruals 179 0
Total accounts payable and accrued liabilities $ 56,770 $ 54,389
v3.24.3
Deferred Compensation and Other Non-current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Other non-current liabilities $ 10,844 $ 10,911
v3.24.3
License and Collaboration Agreements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 24, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenues   $ 67,771 $ 54,515 $ 175,266 $ 130,418  
Otuska | License Agreement Terms            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Upfront payments received           $ 50,000
Regulatory and pricing approval milestone revenue           $ 50,000
Eligible to receive a payment $ 10,000          
Revenues   10,000        
Otuska | License Agreement Terms | Service Revenue            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenues   $ 12,300 $ 12,700 $ 16,700 $ 13,200  
Otuska | License Agreement Terms | Minimum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Tiered royalty percentages on future sales           10.00%
Otuska | License Agreement Terms | Maximum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Tiered royalty percentages on future sales           20.00%
v3.24.3
Shareholder's Equity (Details)
$ in Millions
 9 Months Ended
Feb. 29, 2024
Sep. 30, 2024
USD ($)
shares
Feb. 15, 2024
USD ($)
Class of Stock [Line Items]      
Stock repurchase program, authorized amount     $ 150.0
Stock repurchase program, percentage 0.15    
Stock repurchased during period, (in shares) | shares   3,400,000  
Stock repurchased during period, value   $ 18.6  
Minimum      
Class of Stock [Line Items]      
Stock repurchase program, period 12 months    
Maximum      
Class of Stock [Line Items]      
Stock repurchase program, period 36 months    
v3.24.3
Net Income (Loss) per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:        
Net income (loss) $ 14,350 $ (13,447) $ 4,323 $ (51,145)
Denominator:        
Weighted average common shares outstanding basic (in shares) 143,051 142,847 143,353 143,085
Weighted average common shares outstanding diluted (in shares) 145,651 142,847 145,010 143,085
Net income (loss) per share, basic (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Net income (loss) per share, diluted (in usd per share) $ 0.10 $ (0.09) $ 0.03 $ (0.36)
Stock options, RSUs, performance awards and ESPP        
Denominator:        
Stock options, RSUs, performance awards and ESPP (in shares) 2,600 0 1,657 0
v3.24.3
Share-based Compensation - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 9 Months Ended
Jun. 30, 2021
Sep. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized share-based compensation expense   $ 25.7
Unrecognized share-based compensation expense weighted average recognition period (in years)   1 year 3 months 18 days
Employee Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares) 2,500,000  
Number of shares purchased (in shares)   900,000
Amended and Restated Equity Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of additional shares authorized (in shares) 23,800,000  
v3.24.3
Share-based Compensation - Schedule of Share-based Payment Award Valuation Assumptions (Details) - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]    
Annualized volatility (as percent) 77.00% 71.00%
Risk-free interest rate (as percent) 4.08% 3.92%
Expected life of options in years 5 years 5 years
Estimated forfeiture rate (as percent) 13.00% 12.70%
Dividend rate $ 0.000 $ 0.000
Fair value per common share option (in usd per share) $ 3.82 $ 5.94
v3.24.3
Share-based Compensation - Schedule of Option Activity (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2024
$ / shares
shares
Dec. 31, 2023
$ / shares
Number of shares (in thousands)    
Beginning balance (in shares) | shares 11,556  
Granted (in shares) | shares 325  
Exercised (in shares) | shares (125)  
Forfeited or cancelled (in shares) | shares (2,006)  
Ending balance (in shares) | shares 9,750  
Weighted average exercise price $    
Beginning balance (in usd per share) | $ / shares $ 10.09 $ 10.63
Granted (in usd per share) | $ / shares 5.89  
Exercised (in usd per share) | $ / shares 5.18  
Forfeited or cancelled (in usd per share) | $ / shares 12.81  
Ending balance (in usd per share) | $ / shares $ 10.09  
v3.24.3
Share-based Compensation - Schedule of Allocation of Share-Based Payments (Details) - Performance Share sand Restricted Stock Units (RSUs)
shares in Thousands
 9 Months Ended
Sep. 30, 2024
$ / shares
shares
Number of shares (in thousands)  
Outstanding - Beginning of Period (in shares) | shares 7,807
Granted (in shares) | shares 4,663
Vested (in shares) | shares (2,422)
Forfeited (in shares) | shares (1,673)
Outstanding - End of Period (in shares) | shares 8,375
Weighted average exercise price $  
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) | $ / shares $ 9.29
Weighted average grant date fair value (in usd per share) | $ / shares 6.89
Weighted average grant date fair value (in usd per share) | $ / shares 9.50
Weighted average exercise price (in usd per share) | $ / shares 8.99
Outstanding, Weighted average exercise price - End of Period (in usd per share) | $ / shares $ 7.96
v3.24.3
Share-based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 8,327 $ 11,808 $ 22,650 $ 33,543
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 306 1,975 (1,773) 5,679
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 7,812 9,560 23,427 26,969
Capitalized under inventories        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 209 $ 273 $ 996 $ 895
v3.24.3
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ 457 $ 298 $ 1,952 $ 92
v3.24.3
Related-Party Transactions (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Related Party Transaction [Line Items]    
Other current liabilities $ 1,590 $ 2,388
Other non-current liabilities 10,844 10,911
Dr. Robert T. Foster    
Related Party Transaction [Line Items]    
Payments of deferred compensation 400 100
Employee Benefit Obligations | Dr. Robert T. Foster    
Related Party Transaction [Line Items]    
Other current liabilities 800 800
Other non-current liabilities $ 7,000 $ 7,600
v3.24.3
Restructuring - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Number of positions eliminated, percent 25.00%
v3.24.3
Restructuring - Schedule of Restructuring and Related Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges $ 0 $ 7,755
Employee severance and one time benefits    
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges   6,075
Contract terminations    
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges   1,105
Other costs    
Restructuring Cost and Reserve [Line Items]    
Restructuring costs and asset impairment charges   $ 575
Aurinia Pharmaceuticals (NASDAQ:AUPH)
過去 株価チャート
から 10 2024 まで 11 2024 Aurinia Pharmaceuticalsのチャートをもっと見るにはこちらをクリック
Aurinia Pharmaceuticals (NASDAQ:AUPH)
過去 株価チャート
から 11 2023 まで 11 2024 Aurinia Pharmaceuticalsのチャートをもっと見るにはこちらをクリック